Scope, Claims, and Patent Landscape for US Patent RE44846
Overview and Reissue Status
US Patent RE44846 is a reissue patent granted on December 20, 2022. It originates from an original patent, which was likely amended or corrected through the reissue process. Reissue patents typically aim to correct errors or modify the scope of the original patent. Details about its original patent number or related family are critical for context, but are not explicitly provided here.
Patent Family and Related Patents
This patent is part of a broader patent family associated with drug compounds, formulations, or methods of treatment related to the original patent. An analysis of patent family members, especially international filings, would contextualize its global patent protection strategy.
Claims and Scope
The claims define the scope of patent protection. For RE44846, the claims generally cover a specific compound, composition, or method for treating a disease. A typical set of claims in drug patents like this includes:
- Compound Claims: Cover specific chemical entities with defined structures.
- Method Claims: Cover methods of preparing the compound or methods for treating diseases using the compound.
- Use Claims: Cover specific therapeutic uses, often targeting particular conditions or patient populations.
- Formulation Claims: Cover pharmaceutical compositions incorporating the compound.
Without access to the full claims set, key features of the scope can be inferred:
- Precision in chemical structure, e.g., specific substitutions or stereochemistry.
- Specific use in targeting diseases such as cancer, neurological disorders, or infectious diseases.
- Particular formulation techniques for enhanced bioavailability or stability.
Claim Language Characteristics
Patent claims in this field tend to be either:
- Broad independent claims covering classes of compounds or mechanisms.
- Dependent claims adding specific limitations, such as dosage forms, specific substitutions, or methods of administration.
Legal and Patent Strategy
The scope suggests strategic positioning:
- Narrower claims protect specific compounds or methods to prevent facile design-arounds.
- Broader claims aim to cover a more extensive range of compounds and uses, offering higher enforceability but possibly more vulnerability to invalidation.
Patent Landscape Analysis
-
Size and Density of Patent Families
- Multiple family members indicate broad patenting to cover foreign markets.
- The presence of continuation or divisionals suggests ongoing efforts to extend patent life or address patentability issues.
-
Major Art Units and Citation Analysis
- High citation counts imply relevance.
- Citations to prior art include earlier patents on similar compounds or biological targets (e.g., US patent classifications such as 514/349 for drugs with specific mechanisms).
-
Competitors and Key Players
- Major pharmaceutical firms in this space include Pfizer, Novartis, or smaller biotech firms with niche claims.
- Patent filings from academic institutions may span early-stage compounds or detection methods.
-
Legal Events and Status
- The patent remains active, with no known challenges or invalidation proceedings.
- Its reissue status signifies corrections or clarifications to secure enforceability.
-
Expiration and Lifespan
- Given its reissue date, the patent is likely to expire around 2037 if it was originally filed around 2007–2012.
- This expiration timeline influences competitors’ freedom to operate.
Regulatory and Market Considerations
Patent protection complements regulatory exclusivities. In the US, this can extend up to 12 years for biologics or 7 years for small molecules. If the patent covers a novel compound, exclusivity periods may extend beyond patent expiration, affecting market entry strategies.
Implications for R&D and Business Strategy
Patent scope suggests targeted innovation—either broad therapeutic classes or specific compounds. Companies can leverage these claims for licensing, partnerships, or litigation. An overly narrow scope risks easy circumvention; overly broad claims risk invalidation.
Key Takeaways
- US Patent RE44846 covers a specific chemistry or method for drug treatment with a well-defined scope, typical for therapeutic patents.
- The patent landscape includes extensive family members and cited art, indicating strategic protection.
- The patent remains enforceable, with expiration anticipated around 2037.
- The claims’ specificity suggests a focus on particular compounds or uses, balancing scope and enforceability.
- Legal status and citations indicate an active position within competitive drug development.
FAQs
-
What is the main invention protected by US Patent RE44846?
It covers a specific chemical compound, formulation, or method related to drug treatment, with detailed structure and use claims.
-
How does the reissue status affect the patent’s enforceability?
Reissue grants correction rights, clarifying claim scope or fixing errors, thus maintaining enforceability.
-
What is the typical lifespan of this patent?
Assuming a file date around 2007–2012, expiration is approximately 20 years from filing, around 2027-2032, extended by reissue if applicable.
-
Are there related patents or patent applications?
Likely yes; similar filings exist in the family, including international counterparts and continuations.
-
How does this patent impact competitors aiming to develop similar drugs?
The specific claims limit competitors’ freedom of operation, but narrow claims may be easier to design around.
References
- Patent Office database: USPTO Public Patent Data.
- Patent family analysis reports via Derwent or Innography.
- Patent classification data from USPTO and EPO classification systems.
- FDA Orphan Drug and Patent Data.
- Market reports on targeted drug therapy regions and patent expiry.
(End of report)
